Tango Therapeutics Inc

For the period ended Jun 30, 2024. Filed Aug 7, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 7, 2024

TNGX$24.30+6.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,
	2024	2023	2024	2023
Collaboration revenue	$7,775	$9,598	$14,246	$15,364
License revenue	12,100	5,000	12,100	5,000
Total revenue	19,875	14,598	26,346	20,364
Operating expenses:
Research and development	38,654	28,671	76,719	56,710
General and administrative	10,773	9,174	21,434	17,188
Total operating expenses	49,427	37,845	98,153	73,898
Loss from operations	(29,552)	(23,247)	(71,807)	(53,534)
Other income:
Interest income	2,071	1,450	4,268	2,511
Other income, net	1,995	1,151	4,179	2,369
Total other income, net	4,066	2,601	8,447	4,880
Loss before income taxes	(25,486)	(20,646)	(63,360)	(48,654)
Provision for income taxes	(65)	(64)	(105)	(64)
Net loss	$(25,551)	$(20,710)	$(63,465)	$(48,718)
Net loss per common share – basic and diluted	$(0.24)	$(0.23)	$(0.58)	$(0.55)
Weighted average number of common shares outstanding – basic and diluted	108,314,279	88,354,590	108,692,822	88,281,368
Net loss	$(25,551)	$(20,710)	(63,465)	(48,718)
Other comprehensive (loss) income:
Unrealized (loss) gain on marketable securities	(77)	684	(520)	2,188
Comprehensive loss	$(25,628)	$(20,026)	$(63,985)	$(46,530)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.